Updated on 30 January 2015
Austrianova has opened a new facility in Singapore
Singapore: Singapore based biotech firm, Austrianova, has opened a new facility in Singapore to perform research and development and translational research activities for its cell encapsulation technologies, Cell-in-a-Box and and Bac-in-a-Box.
The company recently expanded in Thailand for good manufacturing practice (GMP) activities, including production of biomedical cell products for clinical use.
Mr Lim Chuan Poh, chairman, A*Star was among the guests present during inauguration.
Mr Brian Salmons, CEO, Austrianova, said, "We are pleased to move to the new and larger facilities which have been custom designed to suit our needs at such a prestigious location. The new headquarters
will allow us to expand our activities in Singapore".
Dr John Dangerfield, COO, Austrianova, stated, "The move from our former location at the Biopreneur lab in Centros to our new base in Synapse means that we are still located at the heart of the internationally renowned Biopolis, among leading private and public research institutes, incubator research units, translational and clinical researchers and medical technology research".
Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-n-a-Box) and bacterial (Bac-in-a-Box) cells. Cell-in-a-Box protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific
sites in patients.
Bac-in-a-Box is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability for extending storage under lyophilized conditions and protection in stomach acid.